Integrating GLP-1 agents with other protective medications may allow providers to address multiple pathways driving kidney damage
This happens because these inhibitors can cause changes in the bodys acid levels, making metformins side effects more severe
reported mass can depend on the supplied molecular form
The mTORC1 pathway and ISR are two major amino acid sensing pathways that integrate nutrient availability to cellular adaptations including protein synthesis, metabolism and cell growth 7,8,15,16
In October 2023, A Research Study to See How Semaglutide Works Compared to Placebo in People with Type 2 Diabetes and Chronic Kidney Disease (FLOW) trial assessing the effect of semaglutide versus placebo on the progression of renal impairment in people with T2DM and chronic kidney disease was stopped prematurely due to results of an interim analysis showing significant efficacy of semaglutide with full results due to be released in the first half of 2024 [39]
Parallel efforts are exploring new indications, including neurodegenerative and substance use disorders, metabolic liver disease, arthritis, type 1 diabetes and inflammatory bowel disease
